Supplementary Figure 8. Principal Component Analysis (PCA) of antitumor immune response of therapeutic lysate vaccines. Median survival of various tumor lysate vaccine groups (Figure 2) and cellular (Figure 3) and humoral (Figure 4) were analyzed by PCA using JMP 12 software.
Supplementary Figure 9. (A) H&E stained tissue sections of various organs (Scale bar: Liver – 100 µm, Lung- 100 µm, Heart – 200 µm (PBS-100 µm), Kidney- 100 µm, Colon-50 µm, Spleen-200 µm), and (B-C) anti naïve B cell lysate and anti A20 tumor lysate antibody levels in serum (at 100 dilution; n=3; MP TL + GalCer: n=2) for various vaccine groups at day 128 of therapeutic immunization study as shown in Figure 2A. Data represent Mean ± S.D.